Small cell lung cancer · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CCDE and RT Variant #01 | — | R 3 238 | — | — | — | ~6 | ~R 14 314 indirect | — |
Carboplatin, Etoposide, RT Variant #01 | — | R 2 569 | 21d | — | — | ~4 | ~R 10 275 indirect | — |
Cyclophosphamide, Methotrexate, RT Variant #01 | — | R 2 285 | 77d | — | — | ~1 | ~R 2 285 indirect | — |
CEV and RT Variant #01 | — | R 1 566 | 21d | — | — | ~5 | ~R 7 829 indirect | — |
CAV and RT Variant #01 | — | R 865 | 21d | — | — | ~6 | ~R 5 188 indirect | — |
Cisplatin, Etoposide, RT Partial | — | — | — | — | — | — | — | — |
6 of 6 regimens shown